Schedule 13D Filing by Northstrive Fund II LP and Braeden Lichti for Bluejay Diagnostics, Inc.

Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13D, amending a previous Schedule 13G, concerning their beneficial ownership of Bluejay Diagnostics, Inc. common stock. As of March 10, 2026, Northstrive Fund II LP beneficially owned 11,000 shares (1.13%) and Braeden Lichti beneficially owned 35,500 shares (3.65%). The filing indicates that Northstrive Fund II LP has recommended that the Bluejay Diagnostics Board of Directors explore a potential acquisition of a Phase 1-ready therapeutic asset targeting refractory chronic cough. This opportunity is presented as a means to strengthen the company's clinical pipeline and create shareholder value. The recommendation includes a specific focus on a peripherally selective FAAH inhibitor with potential applications beyond refractory chronic cough. The filing also notes a potential parallel financing opportunity of approximately $5,000,000. The Reporting Persons state their intention to continuously review their investment and may take further actions as they deem appropriate.